From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...

Proposals for the Implementation of a Multidimensional Platform That Allows the Advancement of Oncology Nursing in the Latin American Environment (The INCREASE Proposal) A systematic review was ...

To the Editor: Del Bufalo et al. (April 6 issue) 1 describe the treatment of patients with relapsed or refractory pediatric neuroblastoma with chimeric antigen receptor (CAR)–expressing T cells that ...

Anti-disialoganglioside (GD2)-targeted third-generation chimeric antigen receptor T cells (GD2-CART01) have shown promising efficacy in children with high-risk metastatic, relapsed, and refractory ...

Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. Background: Neuroblastoma is the most common extracranial solid tumor of childhood.

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...

Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is ...

Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...